home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »

portfolio

$80 million

Endocrinology Medical Device

Mar23Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock »

Nov29Tandem Diabetes Care to Draw Down $35 Million under Existing Term Loan Facility with CRG »

Jan12Tandem Diabetes Care Amends Term Loan Facility with CRG »

Sep9Tandem Diabetes Care Announces FDA Approval of t:slim G4 Insulin Pump with CGM Integration »

Jul30Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems »

May19Tandem Diabetes Care Launches t:flex™ Insulin Pump »

Mar4
Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock »

SAN DIEGO, March 4, 2015 /PRNewswire/ -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim® and t:flex™ Insulin Pumps, today announced the closing of its previously announced underwritten public offering of 6,037,500 shares of common stock at a price to the public of $11.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 787,500 shares. All of the shares in the offering were offered by Tandem.

 

BofA Merrill Lynch and Piper Jaffray acted as joint book-running managers for the offering. Deutsche Bank Securities and Stifel acted as co-managers.  

 

A shelf registration statement on Form S-3 relating to these securities was filed by Tandem with the Securities and Exchange Commission (SEC) and declared effective on December 19, 2014. A copy of the final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038 Attention: Prospectus Department, by email at dg.Prospectus_Requests@baml.com; or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or by email at prospectus@pjc.com.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the t:flex Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, California.

 

t:flex is a trademark, and t:slim and Tandem Diabetes Care are registered trademarks of Tandem Diabetes Care, Inc.

Jan12Tandem Diabetes Care Announces FDA Clearance of the t:flex™ Insulin Pump »

Apr9Tandem Diabetes Care and Capital Royalty Amend and Restate Term Loan Facility »

Nov13Tandem Diabetes Care Prices Initial Public Offering »

Jan23Tandem Diabetes Care and Capital Royalty Close Term Loan Facility »